

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Eli Lilly and Company
Enrollment	58 participants

Key Eligibility Criteria

Inclusion (6)

- Have a diagnosis of primary ITP, defined as isolated thrombocytopenia not associated with another known disease process
 - Have documented history of response, defined as 2 or more platelet counts greater than or equal to 50,000/microliter (μL), to at least 1 prior line of therapy. Splenectomy is considered a line of therapy
 - Have relapsed or treatment-resistant primary ITP, with no available therapies known to provide clinical benefit
 - Have a platelet count less than 30,000/ μL on 2 occasions more than 5 days apart in the 15 days before randomization
 - Have adequate liver, renal, and hematologic functions as defined by a table
- ... and 1 more (see full listing online)

Exclusion (6)

- Have a history of any thrombotic or embolic event within 12 months before screening
 - Had a transfusion with blood or blood products or plasmapheresis within 14 days (Phase 1) or within 28 days (Phase 2) of randomization
 - Have significant cardiovascular disease
 - Have a diagnosis or history of hematologic malignancy
 - Have hepatitis B virus (HBV) defined as positive for antigen of hepatitis B (HBsAg) or polymerase chain reaction (PCR) positive for HBV deoxyribonucleic acid (DNA)
- ... and 1 more (see full listing online)

Locations (45 total)

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Stanford University, Stanford, California, United States
MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
... and 42 more locations